Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taurolidine - Geistlich

Drug Profile

Taurolidine - Geistlich

Alternative Names: PerioSept; Taurolin

Latest Information Update: 23 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geistlich
  • Class Alkanesulfonic acids; Antibacterials; Antineoplastics; Thiadiazines
  • Mechanism of Action Lipopolysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Empyema; Peritonitis
  • Phase II Colorectal cancer; Periodontitis
  • Discontinued Septic shock

Most Recent Events

  • 26 Aug 2019 Phase-II clinical trials in Periodontitis (Adjunctive treatment) in USA (IV) (NCT04093895)
  • 24 Jan 2018 Taurolidine is still in phase I/II trials for Periodontitis (Adjunctive treatment) in USA (NCT02313883)
  • 06 Jan 2018 Phase-II development is ongoing for Colorectal cancer in Ireland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top